Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet
[ad_1] New Delhi, January 22 India’s first indigenous vaccine against COVID-19, Covaxin, showed enhanced immune response without any serious side
Read More
tolerable